Perhaps investor awareness of the potential of the company’s pain drug in phase 2 and 3 trials is simply growing. What evidence do investors have that Cara’s approach will succeed? As it turns out, plenty.
Perhaps investor awareness of the potential of the company’s pain drug in phase 2 and 3 trials is simply growing. What evidence do investors have that Cara’s approach will succeed? As it turns out, plenty.